Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Pharma
Asia
Drug Delivery
Executives
Clinical Data
Vaccines
Special Reports
Trending
COVID-19
Cell & Gene Therapy
Podcasts
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Subscribe
Subscribe
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Pharma
Asia
Drug Delivery
Executives
Clinical Data
Vaccines
Special Reports
Trending
COVID-19
Cell & Gene Therapy
Podcasts
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Taiho Pharmaceutical
Pharma
Takeda, Hutchmed hook up on cancer drug for $1.13B
Takeda has gained commercial rights to Hutchmed's cancer drug fruquintinib outside of China for $400M up front, plus $730M in potential milestones.
Kevin Dunleavy
Jan 23, 2023 10:31am
China's reimbursement talks, Sun, GenScript—Fierce Pharma Asia
Jan 20, 2023 9:00am
Servier, Taiho's Lonsurf excels in colorectal cancer upgrade
Jan 18, 2023 3:50pm
J&J-Legend, Takeda, Merck and more—Fierce Pharma Asia
Oct 7, 2022 10:50am
A third FGFR inhibitor is wading into the bile duct cancer arena
Oct 3, 2022 10:30am
Takeda, Sun, Aurobindo, Eisai and more—Fierce Pharma Asia
May 13, 2022 9:45am
